GTC's principal asset is its novel protein production platform,,its principal problem is the encumberances (sp?)throw up by the regulators.. Should the company be searching for a protein that has uses other than medical,,eg. in industry, chemical engineering, nanotechnology, etc which would not require the insane delays created by the FDA????